aminolevulinic acid
aminolevulinic acid: developed by 1 company · 1 clinical trial tracked · 1 FDA decision.
aminolevulinic acid evidence translation
What we can confirm
1 FDA record · 1 tracked trial
What it means
What to watch
Prepared research question
How could aminolevulinic acid → BFRI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| Biofrontera Inc. (BFRI) Actinic Keratosis (Trunk & extremities) | Phase 3 |
Clinical Trials (1)
Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Loco-Regionally Advanced or Recurrent Colorectal Cancer Undergoing Surgery - Phase I/II
Primary endpoint: Accuracy of the fluorescence imaging (Phase I)
FDA Decisions1 records
Frequently asked questions
Who is developing aminolevulinic acid?
aminolevulinic acid is being developed by Biofrontera Inc..
How many clinical trials involve aminolevulinic acid?
BioSniper tracks 1 clinical trial involving aminolevulinic acid.
What is aminolevulinic acid's latest FDA decision?
The most recent tracked FDA decision for aminolevulinic acid is Approval for 1. INDICATIONS AND USAGE AMELUZ, in combination with photodynamic therapy (PDT) using BF-RhodoLED ® or RhodoLED ® XL lamp, a narrowband, red light illumination source, is indicated for lesion-directed and field-directed treatment of actinic keratoses (AKs) of mild-to-moderate severity on the face and scalp. AMELUZ, a porphyrin precursor, in combination with photodynamic therapy using BF-RhodoLED or RhodoLED XL lamp, is indicated for the lesion-directed and field-directed treatment of actinic ker, dated May 10, 2016.